Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Patents
- What makes an invention patentable?
- Novelty
- A simple difference can establish novelty
- Novelty and jurisdiction
- Is it NEW?
- State of the art
- UK Practice (Merrell Dow vs. Norton)
- UK Practice (SmithKline Beecham’s Patent)
- EPO Practice (Decision T314/99)
- EPO Practice (Decision T838/97)
- Prior rights
- Non-prejudicial disclosures
- Novelty – practical points (1)
- European practice
- Enabling disclosures
- Disclaimers
- Disclaimers (example)
- Disclaimers – three possible situations
- Disclaimers (G1/16)
- Generic vs. Specific
- Selection inventions
- Selection inventions (schematic)
- Selection Inventions (Overlapping ranges)
- Smith & Nephew Plc vs. Convatec Technologies
- First medical use of known compound
- Further medical use of known compounds
- Novelty – Practical points (2)
- Novelty – Practical points (patent specification)
- Summary
- Thank you
Topics Covered
- What makes an invention patentable
- Novelty and jurisdiction
- State of the art
- UK & EU practice through examples
- Prior rights
- Non-prejudicial disclosures
- Practical points
- Enabling disclosures
- Disclaimers in novelty
- Generic vs. Specific
- Selection inventions
- First & further medical use of known compound
- Patent specification
Talk Citation
Atkinson, J.D. (2019, January 31). Novelty in patents: a European perspective [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 5, 2024, from https://doi.org/10.69645/XYIS9066.Export Citation (RIS)
Publication History
Financial Disclosures
- Jonathan Atkinson has not informed HSTalks of any conflict of interest.
Novelty in patents: a European perspective
Published on January 31, 2019
43 min
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. My name is Dr. Jonathan Atkinson from HGF Limited in Leeds,
and I am a European Patent Attorney specializing in the field of pharmaceuticals.
I have a degree and a doctorate in chemistry from Oxford University,
and my doctoral thesis is concerns the synthesis of
chiral derivatives of morphine type alkaloids.
In addition to being a UK and European Patent Attorney,
I'm also a fellow of the Royal Society of Chemistry.
Today, I am going to talk to you about the concept of novelty in the field of patents.
0:32
Before I delve into the concept of novelty,
I'll provide a little introductory background regarding the nature of a patent itself.
A patent is granted for a maximum of 20 years,
apart from certain exceptions in the pharmaceutical industry when it can be a little longer.
The patent needs to be renewed annually by paying renewal fees to the patent office.
Patents are granted for novel and inventive, for example
non-obvious inventions and are intended to protect a concept or idea.
The patent only has effects in the country in which it was granted.
The scope of protection afforded by a patent is defined in the language of the claims,
which can be found at the end of the patent's specification.
1:14
We can now consider what makes an invention patentable.
There are five fundamental criteria that must be met if a patent is to be granted.
Firstly, the claimed invention must be novel.
This is the topic that we're going to investigate in more detail today.
Novelty means that the invention is not already in the public domain.
The second criterion is that the claimed invention must be inventive
meaning, it must not be obvious,
taking into account what is known already.
The third criterion is that the invention must be sufficient, meaning that
the invention must be adequately described in
the patent's specification, so that it can be reproduced.
Fourthly, the invention must be capable of industrial application.
This criterion is relatively easily met by most commercially important inventions.
Finally, the fifth criterion is that the invention must
not be one of a number of statutorily excluded categories,
such as discoveries, mental acts,
or computer programs, etc.
Although, in passing, I should mention that there are certain exceptional cases where
subject matter like computer programs and other excluded subject matter may be patented.